The Wnt signal transduction pathway has been implicated in mammary tumorigenesis in the mouse. b-catenin, a key downstream eector of this pathway interacts with and thus activates the Tcf/Lef family of transcription factors. Elevated levels of b-catenin have been found in many human tumors, notably colon carcinomas. Recently, elevated levels of b-catenin have been associated with poor prognosis in human adenocarcinoma of the breast. In order to assess the possible role of b-catenin in mammary carcinoma, we have created transgenic mice bearing the MMTV ± LTR driving an activated form of b-catenin. These mice develop mammary gland hyperplasia and mammary adenocarcinoma, a phenotype very similar to that of transgenic mice expressing an MMTVdriven Wnt gene. Indeed, the histopathology of the mammary tumors in Wnt-mediated adenocarcinoma is identical to that observed in our b-catenin-mediated disease model. Furthermore, putative b-catenin transcriptional targets, cyclin D1 and c-myc, are elevated in bcatenin-mediated mammary tumors and cell lines. These observations support the notion that the oncogenic Wnt pathway operates via b-catenin and its targets in the context of mammary hyperplasia and carcinoma. Oncogene (2001) 20, 5093 ± 5099.
Introduction
b-catenin has a diverse set of functions within the cell. In its capacity to bind components of the actin cytoskeleton, namely E-cadherin and a-catenin, bcatenin plays a role in cell adhesion (reviewed in Bullions and Levine (1998) ). b-catenin is also an integral player in the Wnt signal transduction pathway (reviewed in Polakis (1999 Polakis ( , 2000 ). In a resting cell, bcatenin is phosphorylated by glycogen synthase kinase3b (GSK) in association with adenomatous polyposis coli (APC) protein, an event which targets b-catenin for ubiquitination and subsequent degradation. In response to extracellular Wnt, a signal is transduced through the membrane-bound Frizzled receptor and subsequently through Disheveled, facilitating inhibition of GSK3b. The net result of the Wnt signal is cytoplasmic accumulation of b-catenin and entry of b-catenin into the nucleus. Once in the nucleus, bcatenin associates with Tcf/Lef transcription factors and together these activate downstream targets. Downregulation of b-catenin levels in the nucleus likely occurs via nuclear export by APC, as recently reported (Henderson, 2000; Neufeld et al., 2000; RosinArbesfeld et al., 2000) .
Structure-function analyses of b-catenin and its Drosophila homolog, Armadillo, have been informative. Amino-terminal deletion mutants were shown to have increased stability due to loss of GSK phosphorylation residues (Barth et al., 1997; Munemitsu et al., 1996) . The central portion of b-catenin, comprised of 12 armadillo repeats, facilitates multiple protein interactions, including binding to Tcf/Lef, APC, Ecadherin and a-catenin (Orsulic and Peifer, 1996; van de Wetering et al., 1997) . The carboxy-terminus functions as a transcriptional activation domain, as demonstrated in GAL4 transcriptional assays (van de Wetering et al., 1997 ). An additional, albeit somewhat weaker, transactivation domain may reside in the Nterminal portion of the protein (Hsu et al., 1998) .
A correlation between b-catenin and tumorigenesis has been well established (reviewed in Polakis (2000) ). Mutations and deletions of phosphorylation sites in the amino terminus resulting in stabilization of b-catenin have been identi®ed in numerous human tumors and cancer cell lines, including colon, hepatocellular, ovarian, endometrial and others (reviewed in Polakis (2000) ). Elevated b-catenin levels resulting from mutations in other components of the Wnt signaling pathway, such as loss-of-function APC mutations, are also commonly found. In colon cancer, it is estimated that nearly 85% of tumors contain mutations in APC, with a majority of the remainder containing activating b-catenin mutations (Kinzler and Vogelstein, 1996; Morin et al., 1997) . Mouse models of b-catenin overexpression have recently been generated in an attempt to show a causative role for b-catenin in the onset of tumorigenesis. Gat et al. (1998) demonstrated that mice expressing K14-driven b-catenin (DN87) develop benign hair follicle tumors. In contrast, when placed under the control of the intestinal Fabp1 promoter, b-catenin (DN89) mice did not develop intestinal polyps, although increased branching of the intestinal villi was observed (Wong et al., 1998) . In a subsequent study, intestinal polyps were observed when b-catenin (Dex3) was introduced into the endogenous b-catenin locus by homologous recombination (Harada et al., 1999) .
The mammalian transcriptional targets of b-catenin are beginning to be elucidated. Using SAGE analysis, c-myc was identi®ed as a target of the pathway in human colorectal cells (He et al., 1998) . A search of the database for canonical Tcf/Lef binding sites identi®ed cyclin D1 as an additional b-catenin target (Tetsu and McCormick, 1999) . That study, as well as those of Shtutman et al. (1999) demonstrated regulation of cyclin D1 by b-catenin in colon carcinoma cell lines. However, it is likely that at least some b-catenin targets may be restricted to speci®c cell types. For example, cmyc was not uniformly activated in RK3E cell lines (E1A-immortalized epithelial cell line derived from neonatal rat kidney) transformed by b-catenin (Kolligs et al., 1999) .
Components of the Wnt signaling pathway have been de®nitively linked to mammary tumorigenesis. Several Wnt family members can induce morphological transformation and altered growth characteristics in cultured C57MG mammary epithelial cells (Brown et al., 1986; Wong et al., 1994) . Moreover, studies from our laboratory and others using MMTV transgenic mouse models have demonstrated that both Wnt-1 and Wnt-10b are capable of inducing mammary adenocarcinomas (Lane and Leder, 1997; Tsukamoto et al., 1988) . Mammary tumors were also observed in heterozygous APC Min mice (Moser et al., 1993) . Regarding b-catenin, a recent study indicates that bcatenin activity in human breast tumors correlates with elevated expression of cyclin D1 as well as a poor prognosis (Lin et al., 2000) . A causative role for bcatenin in mammary tumorigenesis, however, has not been established.
In this study, we explore directly whether b-catenin can induce mammary tumorigenesis and, thus, could serve as a downstream eector of the Wnt pathway. To that end, we have generated transgenic mice expressing an activated form of b-catenin in the mammary gland (MMTV-bcatDN). We ®nd that MMTV-bcatDN mice, like mice bearing a Wnt transgene, exhibit hyperplasia of the mammary gland. Furthermore, MMTV-bcatDN mice develop mammary adenocarcinomas, with a histopathology that is identical to that found in MMTV-Wnt transgenic mice. Finally, we show that putative mammalian targets of b-catenin are elevated in MMTV-bcatDN tumors and tumor cell lines.
Results

MMTV-bcatDN transgenic mice
Transgenic mice were generated to investigate a causative role for b-catenin in mammary gland oncogenesis. The transgenic construct consists of an MMTV promoter placed upstream of a truncated bcatenin cDNA lacking the ®rst 90 codons (b-catenin-DN90) tagged with a 3'-KT3 epitope followed by an SV40 polyadenylation (polyA) site. Following injection of the construct into the male pronucleus of embryos and transfer to pseudopregnant foster mothers, 44 pups were born. From these, four transgenic founder mice were identi®ed by Southern blot analysis using a probe for SV40 polyA. All four founder mice passed the transgene to progeny, thereby generating four independent transgenic lines, referred to as MMTV-bcatDN.A-D. Expression analysis revealed that the transgene was expressed in three out of four transgenic lines, namely MMTV-bcatDN.A ± C. The MMTV-bcatDN.A and MMTV-bcatDN.B lines were expanded and chosen for further analysis.
Transgene expression in both MMTV-bcatDN.A and MMTV-bcatDN.B lines is shown in Figure 1 . Northern blot analysis using an SV40 polyA probe detects a high level of expression of the transgene in mammary glands isolated from day 17.5 pregnant females from MMTVbcatDN.A and moderate expression levels in MMTVbcatDN.B (Figure 1a ). To con®rm expression at the protein level, Western blot analysis of mammary gland lysates prepared from day 17.5 pregnant MMTVbcatDN.A mice was performed. An antibody to bcatenin detects endogenous b-catenin in all samples as well as the truncated b-cateninDN90 protein in transgenic mammary glands from MMTV-bcatDN.A, but not from wildtype FVB or MMTV-bcatDN.D (non-expressing transgenic) mammary glands ( Figure  1b) . Analysis of transgene expression in a range of tissues derived from MMTV-bcatDN.A mice reveals the highest levels of expression in the mammary gland, with low levels of expression in a limited number of other tissues, including testis and skeletal muscle ( Figure 1c ). In MMTV-bcatDN.B, transgene expression is detected exclusively in the mammary gland ( Figure  1d ), albeit at lower levels than in MMTV-bcatDN.A. Thus, the MMTV promoter reliably directs expression of the b-cateninDN90 transgene to the mammary gland in MMTV-bcatDN mice.
Mammary gland hyperplasia in MMTV-bcatDN transgenic mice
Whole mount analysis was performed to examine the ductal structure of mammary glands in MMTVbcatDN transgenic mice. As shown in Figure 2 , examination of a mammary gland taken from a wildtype FVB female mouse reveals a branching ductal structure typical of a virgin female. In contrast, inspection of an MMTV-bcatDN.A mammary gland reveals a mosaic pattern characterized by normal ductal structures interspersed with patches of dense epithelium. Examination of a mammary gland from an MMTV-bcatDN.B virgin female similarly reveals a mosaic pattern, with areas of dense epithelium represented to a lesser extent, consistent with the lower level of expression of the transgene in that line. The areas of dense epithelium detected in the transgenic b-catenin tumorigenesis in the mammary gland JS Michaelson and P Leder mammary glands are indicative of mammary gland hyperplasia. The presence of hyperplastic mammary tissue has been con®rmed by hematoxylin and eosin staining of transgenic mammary gland sections (data not shown). Signi®cantly, these ®ndings indicate that overexpression of an activated form of b-catenin in the mouse mammary gland is sucient to induce hyperplasia.
MMTV-bcatDN transgenic mice develop mammary adenocarcinomas
Activated b-catenin cannot only induce hyperplasia of the mammary gland, but is also capable of resulting in neoplasia. A cohort of 16 MMTV-bcatDN.A continuously breeding female mice was followed and inspected on a weekly basis for mammary tumors for a period of 15 months. As shown in Figure 3a, Figure 3a) ; 3/14 in MMTV-bcatDN.B). The founder female from the third transgenic line, MMTVbcatDN.C, also developed a mammary tumor, although this line was not further expanded. The appearance of mammary tumors in three independent transgenic lines strongly supports MMTV-bcatDN as sucient to induce tumorigenesis in the mammary gland.
The histopathology of MMTV-bcatDN tumors was assessed by examination of hematoxylin and eosin stained tumor sections (Figure 3b ). Tumors arising from all three MMTV-bcatDN lines are consistent with classi®cation as microacinar adenocarcinomas. The tumors are characterized by highly disorganized tissue with patches of cells forming small acini lined by neoplastic cells. Under high magni®cation, it is evident that the cells have pleiomorphic nuclei with prominent nucleoli, that the cytoplasm is sparse with a large number of vacuoles, and that there is a high mitotic index among the tumor cells (data not shown). In some cases, invasion into neighboring normal mammary gland tissue is apparent. There is no evidence of metastases to other organs sites. Signi®cantly, the histopathology of the MMTV-bcatDN tumors is identical to that observed in MMTV-Wnt tumors (Lane and Leder, 1997; Tsukamoto et al., 1988) , supporting an oncogenic role of b-catenin in the Wnt pathway in the mammary gland.
Activation of b-catenin downstream target genes in MMTV-bcatDN tumors and cell lines
The ability of b-catenin to induce neoplasia in the mammary gland is likely a result of transcriptional activation of downstream target genes. Candidate target genes have been identi®ed, e.g. cyclin D1 and c-myc, in colorectal cells, although it is unclear whether these are also targets in other organ systems. Our bcatenin tumors provide an in vivo model to test for target gene upregulation in the mammary gland. RNA prepared from a panel of tumors derived from MMTVbcatDN and MMTV-Wnt animals was subjected to Northern blot analysis. Both cyclin D1 and c-myc are upregulated in the majority of b-catenin tumors (11/ 12), particularly in those expressing high levels of the transgene, and in all (3/3) Wnt-1 tumor cell lines (Figure 4) .
Cell lines derived from tumors provide a homogenous population of epithelial cells and thus an additional model in which to test for target gene (Figure 5a ). Expression at the protein level of the b-catenin-DN90 was detected by Western blot with either an antibody against bcatenin or an antibody against the KT3 epitope tag (Figure 5b ).
To test whether the b-catenin-DN90 protein is transcriptionally active in the tumor cell lines, a luciferase reporter assay was employed. Tumor cell lines were transfected with a pTOPFLASH reporter construct, consisting of multimerized Tcf/Lef binding sites upstream of a luciferase reporter gene (van de Wetering et al., 1997) , and assayed for luciferase activity. Dexamethasone-inducible transcriptional activity is detected in the tumor cell lines but not in a normal mammary epithelial cell line, Eph4 (Figure 5c ). Increased levels of transcriptional activity are detected in the tumor cell lines upon cotransfection with a Tcf-4 cDNA construct, likewise in a dexamethasone-inducible fashion. These studies establish that the bcatenin-DN90 protein is expressed in MMTV-b-catDN tumor cell lines and, furthermore, is capable of activating transcription of downstream targets.
Target gene expression was assessed in the b-catenin tumor cell lines. Both cyclin D1 and c-myc are upregulated in all of the tumor lines (10/10) ( Figure  6 ). Taken together, our data suggest that cyclin D1 and c-myc are likely to be in vivo targets of b-catenin in the mammary gland.
Discussion
We have generated a mouse model in which an activated form of b-catenin (MMTV-bcatDN) is overexpressed in the mammary gland. Our ®ndings provide a de®nitive demonstration that b-catenin can induce mammary tumorigenesis. Previously, overexpression of upstream components of the Wnt signal transduction pathway, namely Wnt-1 and Wnt-10b were shown to be oncogenic in the mouse mammary gland. The histopathology of the MMTV-bcatDN tumors is identical to that observed in tumors derived from MMTV-Wnt-1 and MMTV-Wnt-10b. Together, our observations support the notion that b-catenin is likely responsible for the oncogenicity previously associated with Wnt molecules in the mammary gland.
Interestingly, we have observed that MMTV-bcatDN male mice do not exhibit a mammary gland phenotype. This is in contrast to MMTV-Wnt males which develop ductal formations in the mammary fat pad, particularly striking in the case of Wnt 10b (Lane and Leder, 1997). Both Wnt-1 and Wnt-10b males further proceed to develop mammary adenocarcinomas, albeit at a relatively low frequency (Lane and Leder, 1997; Tsukamoto et al., 1988) . In contrast, whole mount analysis revealed only rudimentary epithelial buds in MMTV-bcatDN males, similar to that found in wildtype males (data not shown). Moreover, none of the MMTV-bcatDN male mice (MMTV-bcatDN.A, 0/13; MMTV-bcatDN.B, 0/6) developed mammary adenocarcinomas by 12 months of age (data not shown). This disparity may be due to diering levels of transgene expression in the male, although the transgene is expressed at signi®cant levels in MMTVbcatDN.A males (Figure 1c) . The possibility that MMTV-bcatDN males might eventually develop tumors at a later age also cannot be ruled out. Of note, tumor development in females also has a longer latency in MMTV-bcatDN mice as compared to those in the MMTV-Wnt models. Intriguingly, the dierence could potentially be attributed to b-catenin-independent Wnt signaling (Haertel-Wiesmann et al., 2000; Ziemer et al., 2001) which may activate pathways the consequence of which is an acceleration of the rate of oncogenesis. The role of alternate downstream components of the Wnt pathway in mammary tumorigenesis therefore cannot be ruled out.
The MMTV-bcatDN female mice exhibit mammary gland hyperplasia. In the Fabpl-b-catenin (DN87) (Wong et al., 1998) . However, these mice do not develop intestinal adenocarcinomas. In a more recent report on b-catenin in the intestine, polyp formation was observed when an activated form of b-catenin was expressed from the endogenous locus in intestinal epithelial cells (Harada et al., 1999) . In the keratin promoter model (Gat et al., 1998) , in addition to de novo hair follicle growth, two types of benign tumors were observed in the animals expressing activated bcatenin. In our mammary gland model, we have found that a signi®cant percentage of mice expressing activated b-catenin develop adenocarcinoma of the breast. The strength of the phenotype observed in the MMTV-bcatDN mice is suggestive of the potency of bcatenin as an oncogene in the mammary gland.
b-catenin likely induces tumorigenesis through its ability to transactivate downstream target genes. It is consistent, therefore, that cyclin-D1 and c-myc, known oncogenes are targets of b-catenin. We have found that these target genes are upregulated in the vast majority of b-catenin mammary tumors and tumor cell lines, suggesting that they are in vivo targets of b-catenin in the mammary gland. We have also observed Wisp-1 and Wisp-2 (Wnt induced secreted proteins), genes identi®ed as Wnt/b-catenin targets in Wnt-1 transformed C57MG mammary epithelial cells (Pennica et al., 1998; Xu et al., 2000) , as being upregulated in bcatenin tumor cell lines (data not shown). However, the possibility that the elevated levels of target genes that we have observed are a result of secondary hits occurring during progression of the tumorigenic process or establishment of the cell lines in culture cannot be ruled out.
The MMTV-bcatDN construct used to generate the transgenic mice lacks the N-terminal GSK3b phosphorylation sites yet retains the C-terminal activation domain of b-catenin. Interestingly, Hsu et al. (1998) showed that the N-terminal portion of b-catenin, which is deleted in our transgenic construct, also possesses transcriptional activity. Our ®ndings suggest that the C-terminal transcriptional domain is sucient for oncogenesis in vivo in the mammary gland. Furthermore, the transcriptional targets that we have identi®ed as upregulated in MMTV-bcatDN tumors are necessarily activated independent of the N-terminal activation domain of b-catenin.
Elevated levels of b-catenin were recently observed in a subset of human breast cancers and a correlation was made with a poor prognosis in that patient subgroup (Lin et al., 2000) . In human studies, it is dicult to determine whether b-catenin plays a causative role in tumor formation or whether its upregulation is a secondary eect of the tumorigenic process. Our studies demonstrating the oncogenic capacity of bcatenin in the mouse mammary gland support the notion that activating mutations of b-catenin mutations may represent primary events in the development of human breast cancer.
Materials and methods
Transgenic mice
To generate the MMTV-bcatDN90 construct, the SacII/XbaI fragment from DN90 mouse b-catenin cDNA (a kind gift from W Nelson, Stanford University; Barth et al., 1997) was cloned into the SacII and XbaI sites of pSL301 (Invitrogen), and subsequently removed from pSL301 by digestion with XbaI and XhoI, followed by n-®ll with Klenow enzyme. The DN90 b-catenin fragment was then blunt-end ligated into the EcoRI site (n-®lled) of the MMTV-SV40-Bssk vector, between the murine mammary tumor virus long terminal repeat (MMTV ± LTR) and an SV40 large T antigen intron and polyadenylation signal. Prior to injection, the construct was linearized with SalI and gel puri®ed.
Five nanograms of DNA was injected into the male pronucleus of one-cell stage FVB/N inbred mouse embryos. Pseudo-pregnant SW foster mothers were reimplanted with viable embryos. Tail DNAs isolated from ospring were tested for the presence of the transgene by enzyme restriction with BamHI followed by Southern blot analysis and probing with a 0.9 kb HindIII/BamHI SV40 poly A fragment.
Northern blot analysis
RNA was isolated from tissues, tumors and cell lines using RNA . For RNA blot analysis, 15 ug of total RNA was heat denatured and separated on a 1% agarose gel containing formaldehyde and MOPS. RNA was transferred to a nylon GeneScreen membrane (NEN) in 106SSC and then ®xed to the membrane with UV light. Hybridization was carried out in buer containing 50% formamide/50 mM sodium phosphate/0.8 M NaCl/10 mM EDTA/2.56Denhardts/0.2% SDS/0.34 mg/ml yeast RNA (Gibco-BRL)/0.4 mg/ml sonicated herring sperm DNA.
Transgene expression was detected with the 0.9 kb HindIII/ BamHI SV40 poly A fragment. The c-myc probe is 5.6 kb and spans exons 2 and 3. A probe for cyclin D1 was generated by RT ± PCR with oligonucleotide primers corresponding to bp 608 ± 630 and 968 ± 989 of cyclin D1 cDNA (Smith et al., 1995) . A probe for 18s rRNA was PCR generated with primers corresponding to bp 1244 ± 1264 and 1645 ± 1667 (GenBank accession # X00686.1).
Protein analysis
Mammary tissue or tumors were homogenized and lysates were prepared in buer containing 20 mM HEPES/150 mM NaCl/1% Triton X-100/2 mM EDTA/2 mM EGTA with protease inhibitors. Lysates were run on 8% polyacrylamide gels and then transferred to a PVDF Immobulin-P membrane (Millipore). Monoclonal anti-b-catenin (Transduction Laboratories) and anti-KT3 (Babco) were used as primary antibodies. Horseradish peroxidase linked sheep anti-mouse Ig (Amersham) was used as a secondary antibody, followed by detection by ECL.
Histological analysis
To prepare whole mounts, mammary glands (# 4) were dissected, immediately placed on glass slides, and allowed to dry for 2 ± 3 min. Fixation was carried out overnight at room temperature in Carnoy's solution (95% ethanol: chloroform: glacial acetic acid [6 : 3 : 1]). Following a rinse in 70% ethanol, samples were stained in carmine alum solution (0.2% carmine (Sigma) and 0.5% aluminum potassium sulfate (Sigma)) at 48C overnight. Dehydration was performed in ascending concentrations of ethanol followed by clearing in xylenes. Whole mount samples were stored in methyl salicylate.
Samples were prepared for histologic analysis by placing fresh tissue in Optimal Fix (American Histological Reagent Co.). Paran embedded sections were analysed by Dr Robert Cardi (Center for Comparative Medicine, University of California, Davis, USA).
Tumor cell culture
Tumor tissue was rinsed in PBS, minced with a surgical blade no. 21 (Bard-Parker), and then placed in culture in DMEM-F12 media (Gibco-BRL) containing 2.5% fetal calf serum (Sigma), 10 mg/ml insulin (Sigma), 5 ng/ml epidermal growth factor (Sigma) in the presence of antibiotics at 378C with 7.5% CO 2 . Fibroblasts were periodically removed from expanding tumor epithelial cell lines by brief trypsinization. Cell lines were established following an average of 4 ± 6 passages and 6 ± 10 months in culture. Dexamethasone (Sigma) treated cells were treated at 1 mM for 24 h.
Transient transfection and luciferase assays
The mammary epithelial cell line Eph4 was maintained in culture in DMEM media (Gibco-BRL) containing 10% bovine serum, 2% 200 mM L-glutamine and antibiotics at 378C with 7.5% CO 2 . Cells were grown to 40 ± 50% con¯uency in 6-well plates and transiently transfected using Fugene6 reagent (Boehringer Mannheim) according to the protocol. Lysates were prepared 40 ± 42 h following transfection in Passive Lysis Buer (Promega) and analysed on an Automat LB953 luminometer (Berthold) with automatic injection of luciferase reagent (Promega). Luciferase assays were performed in triplicate. pTOPFLASH luciferase construct, containing three multimerized Tcf binding sites, and a myc tagged version of human Tcf-4, were kindly donated by H Clevers (van de Wetering et al., 1997) . pGL3 control vector (Promega), containing an SV40 promoter and enhancer, was used as a positive control in the luciferase assays.
